 CAMBRIDGE, Mass., Sept. 24, 2021 PRNewswire -- Leap Therapeutics, Inc. Nasdaq:LPTX, a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of a public offering of 27,568,072 shares of its common stock, which includes the sale of an additional 4,740,000 shares of its common stock pursuant to the full exercise of the underwriters option to purchase additional shares, and of pre-funded warrants to purchase 8,771,928 shares of its common stock. 